Actively Recruiting
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Led by Chinese PLA General Hospital · Updated on 2016-01-28
30
Participants Needed
1
Research Sites
782 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chimeric antigen receptor-modified T cells (CART) holds great promise for treatment of tumors. In this trial, CD30 positive Hodgkin's lymphoma and Non-Hodgkin's lymphoma will be treated by CD30-specific CART cells (CART30).
CONDITIONS
Official Title
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female subjects with CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma relapsing after autologous stem-cell transplantation, or refractory to 2 multidrug regimens and/or anti-CD30 antibody treatment
- Newly diagnosed CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma patients unable to receive or complete standard chemotherapy
- Karnofsky or Lansky score greater than 60%
- Expected survival greater than 12 weeks
- Creatinine less than 2.5 mg/dl
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 3 times normal
- Bilirubin less than 2.5 mg/dl
- Pulse oximetry above 90% on room air
- Adequate pulmonary function with FEV1, FVC, and DLCO at least 50% of expected corrected for hemoglobin
- Available autologous T cells with 10% or more CD30 CAR expression determined by flow cytometry
- Patients or legal guardians must sign informed consent acknowledging understanding of this research study and its possible benefits and side effects
You will not qualify if you...
- Active infection such as hepatitis B or C
- Received anti-CD30 antibody-based therapy within the past 6 weeks
- Current use of systemic corticosteroids
- Pregnant or lactating
- Confirmed tumor in pulmonary or archenteric tissues
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
W
Weidong Han, Ph.D
CONTACT
Q
Quanshun Wang, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here